Epitomee Medical
Epitomee Medical is a pioneering health solutions company focused on developing and commercializing innovative ingestible therapeutic devices aimed at tackling prevalent chronic diseases. Their mission is to improve quality of life through safe, effective, and minimally invasive healthcare solutions, including weight management and biologics delivery platforms.
Industries
Nr. of Employees
small (1-50)
Epitomee Medical
Patents
Retentive devices and systems for in-situ release of pharmaceutical active agents
US-11129793-B2
View Details
Retentive devices and systems for in-situ release of pharmaceutical active agents
US-11129793-B2
View DetailsProducts
Epitomee Capsule
A shape-shifting, biodegradable ingestible device that supports weight management by inducing early sensation of fullness and prolonging gastric emptying.
Epitomee Capsule
A shape-shifting, biodegradable ingestible device that supports weight management by inducing early sensation of fullness and prolonging gastric emptying.
Services
Controlled, targeted, and protected delivery of biologics via ingestible devices, enhancing bioavailability and efficacy.
Innovative, drug-free, shape-shifting capsule technology designed to induce satiety and support weight loss.
Controlled, targeted, and protected delivery of biologics via ingestible devices, enhancing bioavailability and efficacy.
Innovative, drug-free, shape-shifting capsule technology designed to induce satiety and support weight loss.
News & Updates
The RESET trial demonstrated the safety and efficacy of Epitomee's weight loss capsule, with significant weight loss and a favorable safety profile.
The FDA has cleared Epitomee's weight management capsule, a drug-free, mechanical device supporting weight loss in adults with BMI 25-40.
Epitomee completed a $51 million IPO on the Tel Aviv Stock Exchange with a pre-money valuation of $200 million.
The RESET trial demonstrated the safety and efficacy of Epitomee's weight loss capsule, with significant weight loss and a favorable safety profile.
The FDA has cleared Epitomee's weight management capsule, a drug-free, mechanical device supporting weight loss in adults with BMI 25-40.
Epitomee completed a $51 million IPO on the Tel Aviv Stock Exchange with a pre-money valuation of $200 million.